Amphetamine Antibody (6F2): sc-57618

Amphetamine Antibody (6F2) is a mouse monoclonal IgG1 antibody that detects Amphetamine protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Amphetamine antibody (6F2) is available as the non-conjugated isotype antibody. Amphetamine protein plays a crucial role in the central nervous system as a potent stimulant, primarily functioning by increasing the release of neurotransmitters such as norepinephrine, dopamine, and serotonin. This mechanism is vital for therapeutic effects, which include appetite suppression and the management of attention disorders. By converting molecular transporters into open channels, Amphetamine enhances neurotransmitter availability in synaptic clefts, thereby facilitating nerve impulse transmission and promoting heightened alertness and concentration. However, Amphetamine′s interaction with neurotransmitter systems also underscores potential for psychological addiction and the development of tolerance with chronic use. Understanding the dynamics of Amphetamine′s action is essential for both clinical applications and the assessment of long-term effects on mental health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Amphetamine Antibody (6F2) References:

1. Amphetamine drugs.  |  FLEMMING, AS. 1960. Public Health Rep (1896). 75: 49-50. PMID: 13823458
2. Transient disruption of attentional performance following escalating amphetamine administration in rats.  |  Kondrad, RL. and Burk, JA. 2004. Psychopharmacology (Berl). 175: 436-42. PMID: 15083258
3. Patterns of amphetamine use in New Zealand: findings from the 2001 National Drug Survey.  |  Wilkins, C., et al. 2004. N Z Med J. 117: U796. PMID: 15107899
4. Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex.  |  Castner, SA., et al. 2005. Biol Psychiatry. 57: 743-51. PMID: 15820231
5. Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists.  |  Jain, R. and Holtzman, SG. 2005. Brain Res Bull. 65: 415-21. PMID: 15833596
6. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats.  |  He, J., et al. 2005. Behav Brain Res. 160: 178-87. PMID: 15836913
7. Mechanisms of neurotransmitter release by amphetamines: a review.  |  Sulzer, D., et al. 2005. Prog Neurobiol. 75: 406-33. PMID: 15955613
8. The neural substrates of amphetamine conditioned place preference: implications for the formation of conditioned stimulus-reward associations.  |  Rademacher, DJ., et al. 2006. Eur J Neurosci. 24: 2089-97. PMID: 17067306
9. Amphetamine-induced dopamine release: duration of action as assessed with the D2/3 receptor agonist radiotracer (-)-N-[(11)C]propyl-norapomorphine ([11C]NPA) in an anesthetized nonhuman primate.  |  Narendran, R., et al. 2007. Synapse. 61: 106-9. PMID: 17117423
10. Protective effects of amphetamine on gastric ulcerations induced by indomethacin in rats.  |  Sandor, V., et al. 2006. World J Gastroenterol. 12: 7168-71. PMID: 17131481
11. Amphetamine, past and present--a pharmacological and clinical perspective.  |  Heal, DJ., et al. 2013. J Psychopharmacol. 27: 479-96. PMID: 23539642
12. Amphetamine-induced hyperthyroxinemia.  |  Morley, JE., et al. 1980. Ann Intern Med. 93: 707-9. PMID: 6782925